Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30483608 | 1.00 | F11 (1.00) | F11 | |
| SCHEMBL21259591 | 1.00 | F11 (1.00) | F11 | |
| SCHEMBL23560938 | 0.87 | F11 (0.78) | F11 | |
| SCHEMBL21259570 | 0.86 | F11 (1.00) | F11 | |
| SCHEMBL21259928 | 0.86 | F11 (1.00) | F11 | |
| SCHEMBL21259623 | 0.86 | F11 (1.00) | F11 | |
| SCHEMBL21259558 | 0.86 | F11 (1.00) | F11 | |
| SCHEMBL23527559 | 0.85 | F11 (1.00) | F11 | |
| SCHEMBL21259704 | 0.85 | F11 (1.00) | F11 | |
| SCHEMBL21259984 | 0.84 | F11 (1.00) | F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | F11 18/4885 |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | F11 18/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | F11 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.